• Featured Product
  • KD/KO Validated

VIRMA/KIAA1429 Polyklonaler Antikörper

VIRMA/KIAA1429 Polyklonal Antikörper für WB, IHC, IF/ICC, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human, Maus

Anwendung

WB, IHC, IF/ICC, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 30166-1-PBS

Synonyme

KIAA1429, VIRMA, MSTP054, virilizer



Geprüfte Anwendungen

Produktinformation

30166-1-PBS bindet in WB, IHC, IF/ICC, Indirect ELISA VIRMA/KIAA1429 und zeigt Reaktivität mit human, Maus

Getestete Reaktivität human, Maus
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen VIRMA/KIAA1429 fusion protein Ag32830
Vollständiger Name KIAA1429
Beobachtetes Molekulargewicht200-210 kDa
GenBank-ZugangsnummerBC003701
Gene symbol KIAA1429
Gene ID (NCBI) 25962
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

VIRMA (KIAA1429) is a key component of m6A methyltransferase (writer) complex that include METTL3, METTL14, WTAP, VIRMA, HAKAI, ZC3H13, and RBM15. VIRMA mediates methylation in the 3'UTR and around the stop codon, thus affecting alternative polyadenylation. VIRMA has been reported to act as an oncogenic factor in breast cancer and liver cancer. KIAA1429 exhibits differential nuclear and cytoplasmic distribution in colorectal cancer samples, and high cytoplasmic expression of KIAA1429 is associated with poor response to chemotherapy. BRAF-mediated phosphorylation of KIAA1429 facilitates its aggregation in the cytoplasm. Furthermore, cytoplasmic KIAA1429 promotes WNT pathway activation by binding and stabilizing FZD7, thereby further enhancing cancer stemness and oxaliplatin resistance (PMID: 40611274). Moreover, this antibody can not recognize short isoforms.